Drugs / Sabatolimab
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04810611 | Jun 2021 → Apr 2024 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04283526 | Nov 2020 → Apr 2024 | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03961971 | Feb 2020 → Nov 2022 | glioblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT03940352 | Jun 2019 → Aug 2024 | acute myeloid leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03066648 | Jul 2017 → Sep 2023 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, premalignant hematological system disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06664879 | Dec 2024 → Jul 2028 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05367401 | Dec 2024 → Oct 2029 | acute myeloid leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04623216 | Sep 2021 → Aug 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04097821 | Sep 2019 → May 2023 | myelofibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02608268 | Nov 2015 → Aug 2022 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT05201066 | Feb 2023 → Feb 2028 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04878432 | Mar 2022 → Oct 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04823624 | Jan 2022 → Nov 2024 | myelodysplastic syndrome | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT04812548 | May 2021 → May 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04150029 | Sep 2020 → Oct 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03946670 | Jun 2019 → Apr 2022 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT04266301 | Jun 2020 → Oct 2024 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sabatolimab | “This study was a first in human (FIH), open-label, Phase I-Ib/II, multi-center study which consisted of a Phase I dose escalation part of sabatolimab (MBG453) as single agent,...” NCT02608268 ↗ |
| Known as | MBG453 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03066648 ↗ |
| Known as | NVP-MBG453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594575 ↗ |
| Action | Inhibit | “blocks the binding of TIM-3 to phosphatidylserine (PtdSer)” NCT03066648 ↗1“Hepatitis A virus cellular receptor 2 inhibitor” CHEMBL4594575 ↗ |
| Modality | Monoclonal antibody | “Anti human TIM-3 monoclonal antibody.” NCT02608268 ↗ |
| Route | Intravenous | “MBG453 administered via intravenous (i.v.) infusion” NCT02608268 ↗ |
| Target | HAVCR2 | “Hepatitis A virus cellular receptor 2 inhibitor” CHEMBL4594575 ↗ |